NCT05777109UNKNOWNanonymous

A Dual-center, Randomized, Double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, Pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults

Sponsor

Source record

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

HS-20090, Xgeva®

Indication / condition

AI-normalized

Healthy

Intervention

Source record

HS-20090, Xgeva®

Related intelligence directories

Indication directory: Healthy Modality directory: monoclonal antibody Target directory: HS-20090

Source & freshness

Source record

NCT ID

NCT05777109

Original source

ClinicalTrials.gov

Source last updated

Aug 23, 2023

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05777109

Title

A Dual-center, Randomized, Double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, Pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Status

UNKNOWN

Phase

PHASE1

Condition raw

Healthy

Condition normalized

Healthy

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

HS-20090, Xgeva®

Target normalized

HS-20090, Xgeva®

Interventions

HS-20090, Xgeva®

Public preview

Source record

A Dual-center , Randomized, double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Dual-center, Randomized, Double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, Pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT05777109

Status

UNKNOWN

Phase

PHASE1

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Executive brief

Investment-Ready Snapshot

A Dual-center , Randomized, double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedAug 23, 2023

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05777109

Indication

Healthy

Modality

monoclonal antibody

Target

HS-20090, Xgeva®

Intervention

HS-20090, Xgeva®

Source record